Last updated: May 16, 2026
In this article
- Understanding Bladder Cancer in Dogs
- The Scottish Terrier Picture
- Risk Factors Beyond Breed
- Recognizing the Warning Signs
- Diagnostic Workup and the BRAF Test
- Treatment Options
- Managing Urinary Obstruction
- Prognosis and Quality of Life
- Living with a Bladder Cancer Diagnosis
- Cost, Adoption, and Senior Care
- Frequently Asked Questions
Understanding Bladder Cancer in Dogs
Bladder cancer in dogs is most often transitional cell carcinoma (TCC), also called urothelial carcinoma, a cancer that arises from the cells lining the bladder and urethra. Unlike some cancers that announce themselves with a palpable mass, TCC announces itself by mimicking a chronic urinary tract infection that won’t quite clear up. By the time many dogs are diagnosed, they have been treated empirically for UTI for weeks or months, with antibiotics seeming to help briefly before symptoms recur. Recognizing this pattern earlier saves valuable diagnostic and treatment time.
TCC is biologically aggressive. It tends to grow at the trigone of the bladder, the triangular region where the ureters enter and the urethra exits, which makes complete surgical removal essentially impossible because of the anatomy. It also metastasizes to the iliac and sublumbar lymph nodes, lungs, and bones. Despite these challenges, modern treatment approaches can give many dogs months to over a year of good quality life. For closely related context, see our transitional cell carcinoma in dogs article.
The Scottish Terrier Picture
Scottish Terriers have one of the most dramatic breed predispositions of any cancer in any species. Compared to mixed-breed dogs, Scotties are at substantially elevated risk for TCC, with risk estimates varying across studies but all pointing to a several-fold to many-fold increased risk. The reasons appear to be a combination of genetic susceptibility and possibly environmental interactions, with some research linking herbicide exposure (particularly older lawn-care formulations containing 2,4-D and similar compounds) to elevated TCC risk in predisposed breeds.
Other over-represented breeds include Shetland Sheepdogs, West Highland White Terriers, Beagles, and Wire Fox Terriers. Female dogs are over-represented compared to males, the opposite of most cancers in dogs. Dogs over the age of six are at the highest risk, with most cases diagnosed in seniors. For Scottish Terrier owners, periodic screening with urine cytology and the BRAF mutation urine test starting in middle age is sometimes recommended; ask your vet about whether this is appropriate for your dog.
Risk Factors Beyond Breed
Beyond breed, female sex is a notable risk factor in dogs (in contrast to humans, where male sex is the dominant risk factor). Obesity, exposure to certain herbicides (older 2,4-D formulations and similar), and possibly exposure to passive cigarette smoke have been associated with elevated risk in some studies. Spayed dogs may be at modestly elevated risk compared to intact females, though this finding is not consistent across studies.
Practical preventive interventions include avoiding the use of broad-leaf lawn herbicides in spaces where dogs spend extensive time, maintaining lean body weight, and providing fresh water and frequent opportunities to urinate. None of these is a guarantee, but they’re the modifiable factors. Pet insurance taken out before symptoms appear remains the strongest financial-protection tool for senior cancer diagnoses.
Recognizing the Warning Signs
The classic presentation of TCC is a UTI that won’t quite clear up. Signs include hematuria (blood in the urine), pollakiuria (urinating frequently in small amounts), stranguria (straining to urinate), and sometimes incontinence. Antibiotics may briefly improve symptoms because secondary bacterial cystitis is common, but symptoms recur as the underlying tumor continues to irritate the bladder lining.
As the disease progresses, additional signs may appear. Difficulty urinating, weak urine stream, complete urinary obstruction (an emergency), rear-leg lameness from bone metastasis, decreased appetite, and weight loss are all part of the picture. Some dogs present with hematuria as the only sign and are otherwise apparently healthy. Any senior dog with persistent urinary symptoms that don’t fully resolve with antibiotics deserves diagnostic workup beyond more empirical antibiotic courses.
Diagnostic Workup and the BRAF Test
The workup begins with thorough history, physical exam, urinalysis with urine culture, and routine bloodwork. Persistent hematuria with sterile urine cultures should raise the index of suspicion. From there, abdominal ultrasound is the imaging tool of choice, providing clear visualization of the bladder, identification of mass lesions, and assessment of regional lymph nodes and other abdominal organs. Three-view chest radiographs screen for pulmonary metastasis.
The BRAF mutation urine test (CADET BRAF) is one of the most useful diagnostic advances in canine bladder cancer. A urine sample is tested for the BRAF V595E mutation, which is present in a substantial majority of canine TCC cases and essentially absent in non-tumor conditions. A positive test in a dog with appropriate clinical signs is highly supportive of TCC and can avoid the need for invasive biopsy in some cases. Definitive tissue diagnosis usually comes from traumatic catheterization (a non-surgical technique to collect cells through a catheter), cystoscopy with biopsy, or surgical biopsy.
Ask your primary vet for a referral to a board-certified oncologist (ACVIM-Oncology) once the diagnosis is suspected. Avoid percutaneous (through-the-skin) biopsy of bladder masses because of the risk of seeding tumor cells along the needle tract.
Treatment Options
Treatment of canine TCC is rarely curative because of the trigonal location and the high rate of microscopic metastasis at diagnosis. The realistic goals are slowing progression, controlling symptoms, and preserving quality of life. Multimodal medical management is the most common approach, combining NSAID therapy with chemotherapy.
Piroxicam is a non-steroidal anti-inflammatory drug that has shown anti-tumor activity in TCC, with response rates and duration that justify its inclusion in most treatment protocols. Other NSAIDs in the same class (the COX-1 inhibitors) are sometimes used. Newer COX-2 selective options like deracoxib have also been evaluated. Chemotherapy options include mitoxantrone, vinblastine, chlorambucil, and various combinations. Toceranib (Palladia) is sometimes used in TCC protocols.
Surgery has limited role because of the trigonal location, but partial cystectomy is feasible for tumors in surgically accessible locations (apex of bladder away from the trigone). Radiation therapy is sometimes used for local control or palliation. Urethral or ureteral stenting can address obstruction. Each treatment plan is tailored by your oncologist to the specific tumor location, stage, and the dog’s overall condition.
Managing Urinary Obstruction
Urinary obstruction from a tumor blocking the urethra is a true emergency. A dog who cannot urinate, who is straining repeatedly with no urine produced, and who is becoming systemically ill needs immediate care at a 24-hour veterinary hospital. Stabilization typically involves intravenous fluids, electrolyte management, and either temporary urinary catheter placement or, if catheterization is not possible, cystocentesis (sterile bladder tap) to relieve pressure. Definitive options include urethral stenting, cystostomy tube placement, or urinary diversion surgery.
Prevention of obstruction is part of treatment planning. Dogs on TCC protocols benefit from owners who are attentive to early signs of difficulty urinating and who have an emergency plan in place. Knowing your nearest 24-hour facility ahead of time matters.
Prognosis and Quality of Life
Prognosis is guarded for TCC because of the typical trigonal location and high metastasis rate. Without treatment, survival is typically a few months from diagnosis. With multimodal medical management (NSAIDs plus chemotherapy), many dogs gain meaningful additional time, often six months to over a year of good-quality life. Surgical candidates with resectable apex tumors can do considerably better. Specific survival numbers vary by stage, treatment, and individual response; your oncologist can give realistic expectations based on your dog’s specifics.
Quality of life is the metric that matters most. A dog who is urinating without distress, eating well, and engaging with the household is doing well by the most important measure. Pain control, anti-nausea medications, and supportive care for any complications are essential. The ASPCA Pet Loss Hotline at 877-474-3310 is a resource for families navigating end-of-life decisions for cancer patients.
Living with a Bladder Cancer Diagnosis
Day-to-day life with a TCC diagnosis tends to settle into a routine of medication, recheck visits, and watchful monitoring once treatment starts. Most dogs on multimodal medical management feel reasonably normal, with energy, appetite, and engagement preserved much of the time. Frequent opportunities to urinate are important; long stretches without bathroom breaks can be uncomfortable for dogs with bladder tumors. A walking schedule that includes more frequent short outings rather than fewer long ones often helps.
Hydration matters too. Always-available fresh water, sometimes supplemented by adding water or low-sodium broth to food, helps maintain urine flow and may reduce bladder irritation. Some dogs benefit from a litter-pan-style indoor bathroom option for nighttime use. Communicate any worsening hematuria, straining, or partial obstruction signs to your veterinary team promptly because timely adjustments to therapy can prevent emergencies.
Cost, Adoption, and Senior Care
Treating bladder cancer is expensive. Diagnostic imaging, BRAF testing, biopsy or cystoscopy, chemotherapy, possible surgery, possible stenting, hospitalizations, and follow-up monitoring can total many thousands of dollars over the course of treatment. Specific dollar figures vary by region and complexity. Ask your vet about cost ranges in your area, and consider CareCredit, scratchpay, payment plans, and rescue-side aid funds. Our veterinary specialist cost breakdown walks through realistic ranges.
For broader context, our cancer in dogs overview covers the most common canine cancer diagnoses. Senior dogs facing cancer are no less worth fighting for, and many treatment paths produce meaningful additional time. Browse our adopt-a-dog hub for senior dogs looking for soft landings.
Frequently Asked Questions
What is the most common bladder cancer in dogs?
Transitional cell carcinoma (TCC), also called urothelial carcinoma, is by far the most common bladder cancer in dogs. It typically grows at the trigone of the bladder, making complete surgical removal essentially impossible.
Why are Scottish Terriers at such high risk?
Scottish Terriers have one of the most dramatic breed predispositions for bladder cancer of any breed for any cancer. The reasons appear to be genetic susceptibility, possibly modified by environmental factors like herbicide exposure. Periodic screening starting in middle age is sometimes recommended.
What is the BRAF test for bladder cancer?
The CADET BRAF test detects the BRAF V595E mutation in a urine sample. The mutation is present in a substantial majority of canine TCC cases. A positive test in a dog with appropriate clinical signs strongly supports the diagnosis and can sometimes avoid the need for invasive biopsy.
Can bladder cancer in dogs be cured?
Cure is rarely possible because of the typical trigonal location and high rate of microscopic metastasis at diagnosis. The realistic goals are slowing progression, controlling symptoms, and preserving quality of life. Many dogs gain six months to over a year of good-quality life with multimodal treatment.
What is piroxicam for bladder cancer?
Piroxicam is a non-steroidal anti-inflammatory drug with anti-tumor activity in canine TCC. It is commonly used as part of treatment protocols, often alongside chemotherapy. Your vet will monitor closely with periodic bloodwork because of GI and kidney risks.